Introduction
Obstructive sleep apnea (OSA) is a common disorder with major neurocognitive and cardiovascular sequelae. Recent estimates suggest that nearly a billion adults (aged 30 to 69 years) worldwide have OSA with the majority suffering from a mild disease [
1]. The decision to treat mild sleep apnea presents a challenge in clinical practice [
2]. Some patients with mild OSA have a substantial burden of symptoms, whereas others may be at risk of disease progression over time, in part, due to weight gain [
3]. A growing body of evidence suggests that mild OSA is associated with an increased risk of stroke [
4], hypertension, impaired quality of life, and a predisposition to early atherosclerosis [
5]. Moreover, treatment of mild OSA can improve blood pressure suggesting that diagnosing and treating mild OSA is of clinical value [
6].
A number of options exist for the management of mild OSA. PAP therapy (positive airway pressure) remains the primary modality but adherence is challenging particularly with mild disease [
7]. Lifestyle changes such as weight loss, oral appliances, and upper airway surgery, are alternative options although their efficacy among those with mild OSA is highly variable. Thus, there is a general acknowledgement that new therapies are required. Although the pathogenesis of sleep apnea varies across patients, anatomical compromise can be overcome by increased activity in pharyngeal dilator muscles [
8]. As airway protective mechanisms vary across patients, pharyngeal collapse occurs in those who are anatomically susceptible. In addition, there are data suggesting the occurrence of upper airway neuromyopathy in some patients with snoring and OSA [
9]. Upper airway “re-education therapy” [
10] and inspiratory muscle training [
11,
12] provide additional means through which patients with OSA may experience clinical improvement. Given the advancement in defining specific physiological traits and OSA endotypes [
13], it is very likely that there is a subset of patients that is most amenable to upper airway training.
Recent work has shown that training of the upper airway dilator muscles using daytime neuromuscular electrical stimulation (NMES) is feasible and may lead to improvements in OSA severity. The current study expands on the previous work [
14,
15] to test the hypothesis that daytime upper airway muscle electrical stimulation would lead to clinical improvements during sleep in those with mild sleep apnea. The study by Baptista et al. showed a significant improvement in primary snoring, but did not look explicitly at individuals with mild OSA given the patient heterogeneity [
16]. This paper is a secondary analysis of the subset of these individuals with mild OSA.
Discussion
The results of this study show that daytime transoral neuromuscular training for mild OSA was associated with improvements in disease severity and accompanying symptoms of snoring, sleepiness, and overall compromise in sleep quality. Our findings are important for a number of reasons. First, we have seen improvements in mild sleep apnea, such that the resulting average AHI falls within a normal range among responders. Second, we have observed improvements in both objective and subjective snoring using validated objective snoring measurements from sleep studies and bed partner diaries. Third, the NMES technology was well tolerated with no serious adverse events reported. Unlike PAP or oral appliances that require night-time use, the NMES device used in this study is a daytime therapy device with a low burden of use for the patient. This approach makes patient tolerability and the acceptance of the therapy much more feasible. Thus, we believe that this new technology is worthy of further study and consideration for the treatment of mild OSA.
A number of options exist for the treatment of mild OSA but many of these modalities are hampered by poor patient adherence and intolerance. PAP provides benefits for some patients and is widely considered to be the gold standard treatment of OSA. Historically, this therapy is variably tolerated by patients, with one study estimating long-term adherence with PAP to be anywhere from 40 to 85% [
19].
Alternative therapies used to manage mild OSA include oral appliances, upper airway surgery, and diet/exercise. The efficacy of these treatments is highly variable and we lack a robust ability to predict who is likely to respond [
20,
21]. Oral devices and appliances are not a homogenous group as they differ greatly in both design and action, which makes their effectiveness difficult to predict.
Hypoglossal nerve stimulation (HNS), a surgically implanted nerve stimulator to overcome obstructive events by tongue stimulation during sleep, has become commercially available in recent years. They are indicated for patients with moderate to severe OSA who have failed CPAP therapy. HNS devices have been associated with complications such as infections and device malfunction [
22]. The cost of HNS remains a major limiting factor for widespread adoption and the cost-effectiveness of HNS devices continues to be uncertain [
23].
While upper airway surgery remains another treatment choice, the surgical treatment for OSA in adults has traditionally been considered of variable benefit [
21]. Sethkumar et al. noted that the wide range of surgical procedures available made site-specific and targeted surgery with rigorous and correct patient selection critical to achieve optimal results [
24]. The stringent nature of the selection criteria limits the number of patients who can benefit from this treatment.
Training of the upper airway musculature and its relationship to improved OSA is not a new concept. A paper in the BMJ in 2006 showed that the use of the didgeridoo led to improvements in sleep-disordered breathing [
25]. The use of this instrument does require considerable pharyngeal muscle activation and thus in theory the instrument could be training the dilator muscles of the upper airway yielding benefits during sleep. A group in Brazil has also reported that a defined upper airway muscle exercise regimen could improve sleep-disordered breathing among participants although the mechanisms behind this finding are unclear [
26]. Other studies have found that corresponding oropharyngeal exercises can alleviate moderate OSA [
27]. The former paper was a systematic review and meta-analysis where the authors stipulated that these positive effects were caused by a change in oropharyngeal muscle tone.
However, exercise-based approaches require practice/training and are probably implemented with considerable variability. While NMES does require daily practice, the ease of use and patient-titrated effect may allow for more sustained, longitudinal benefits. The principle of NMES has been attempted in the treatment of OSA. In a randomized, placebo-controlled study on electrical stimulation of the tongue musculature, Randerath et al. noted a significant effect on snoring although AHI remained unchanged [
28]. This study included patients with moderate and severe OSA (baseline AHI 10–40 events/hour) and a device that used electrodes positioned in the submental area relying on transcutaneous stimulation through the neck externally. Our trial included patients with mild OSA only and is an entirely intraoral device with transmucosal stimulation directly onto the tongue muscles. Our results support clinically and statistically significant improvements in AHI, objective snoring sound as well as the subjective measures of daytime sleepiness (ESS), sleep quality (PSQI), and bed partner reported snoring (VAS).
Despite our study’s strengths, we acknowledge a number of limitations. First, the absence of a sham comparator means that the observed improvements may have been a result of a placebo effect and/or non-specific changes in health behavior such as diet, exercise, or alcohol intake. However, we did not instruct our participants on any of these factors and thus doubt any major change in health behavior during our study given the longstanding nature of the snoring complaints and short therapy period of 6 weeks. Furthermore, the possibility of a placebo effect is partially mitigated by the inclusion of objectively assessed endpoints, and the fact that consistent changes were observed for objectively measured and self-reported endpoints. However, ongoing clinical trials do include a control arm (
https://clinicaltrials.gov/ct2/show/NCT05252156). Second, the open-label nature of the study prevented the sleep study staff from being blinded to the pre or post-therapy status of the patient. Importantly, however, the sleep studies were analyzed using the validated auto-scoring algorithms in the zzzPAT software (Itamar Medical), with manual adjustment limited to reviewing the signals for irregularities/artifacts, thus minimizing the possibility that the lack of blinding impacted the interpretation of the objective snoring, AHI, or ODI endpoints [
29,
30]. Additionally, the primary statistical analysis was performed by an independent statistician. Third, we did not assess hard outcomes such as cardiovascular disease endpoints or neurocognitive performance. These outcomes remain the key endpoints to consider and should be assessed in larger long-term trials. Although we have demonstrated a reduction in clinical indices associated with sleep-disordered breathing, we cannot conclusively determine whether our interventions result in the desired improvements in OSA complications. Ongoing clinical trials include polysomnography in order to assess better the differences in rapid eye movement (REM) versus non-REM AHI as well as the impact of sleep position. Additionally, it bears mention that we excluded individuals with a BMI > 35 kg/m
2 as we believe it is less likely that NMES will have a treatment effect in morbid obesity. Finally, we did not study the mechanisms underlying our observed improvements, but have ongoing efforts to record genioglossus muscle function before and after stimulation to explore these mechanistic aspects (NCT03913494). In addition, we believe that our therapeutic approach may be helpful for particular OSA endophenotypes (such as those with lower upper airway gain) which we plan to study in future trials [
31].
Despite these limitations, we believe that our new findings are of interest and represent an early step in a research pathway worthy of further pursuit and consideration for therapeutic options for mild OSA. We considered this single-arm trial design to be an appropriate next step in order to define the impact of NMES over time before proceeding to subsequent trials incorporating a non-therapeutic comparator, followed by comparative-effectiveness trials. Future studies will be able to include the impact of time of day device use on sleep outcomes as well as provide more granular adherence/individual monitoring of device settings.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.